Table 4.
Relationship between COX-2 and MDR1/P-gp (detected with C219 or JSB-1 antibodies) expression and clinicopathologic factors
| Characteristics | No. of patients (%) | ||||||||
| COX-2 positive | COX-2 negative | P value Chi2 test | C219 high (IRS 4–12) | C219 low (IRS 0–3) | P value Chi2 test | JSB-1 high (IRS 4–12) | JSB-1 low (IRS 0–3) | P value Chi2 test | |
| pT | |||||||||
| 1 | 8 (8) | 9 (9) | 7 (7) | 10 (10) | 8 (8) | 9 (9) | |||
| 2 | 37 (36) | 49 (47) | 35 (34) | 51 (49) | 36 (35) | 50 (48) | |||
| 4 | 1 (1) | 0 (0) | 0.4954 | 1 (1) | 0 (0) | 0.7869 | 1 (1) | 0 (0) | 0.6306 |
| pN | |||||||||
| 0 | 10 (10) | 19 (18) | 11 (11) | 18 (17) | 11 (11) | 18 (17) | |||
| 1 | 36 (35) | 39 (37) | 0.2117 | 32 (31) | 43 (41) | <0.001 | 34 (33) | 41 (39) | <0.001 |
| Stage | |||||||||
| I | 1 (1) | 2 (2) | 1 (1) | 2 (2) | 1 (1) | 2 (2) | |||
| IIa | 16 (15) | 24 (23) | 16 (15) | 24 (23) | 17 (16) | 23 (22) | |||
| IIb | 28 (27) | 32 (31) | 25 (24) | 35 (34) | 29 (28) | 31 (30) | |||
| IIIb | 1 (1) | 0 (0) | 0.6628 | 1 (1) | 0 (0) | 0.5915 | 1 (1) | 0 (0) | 0.5874 |
| Grade | |||||||||
| 2 | 26 (25) | 45 (43) | 25 (24) | 46 (44) | 26 (25) | 45 (43) | |||
| 3 | 20 (19) | 13 (13) | 0.0135 | 18 (17) | 15 (14) | <0.001 | 19 (18) | 14 (13) | < 0.001 |
| Menopause | |||||||||
| Praemenopausal | 12 (12) | 18 (17) | 13 (13) | 17 (16) | 14 (13) | 16 (15) | |||
| Postmenopausal | 34 (33) | 40 (38) | 0.4553 | 30 (30) | 44 (42) | 0.8307 | 31 (30) | 43 (41) | 0.9703 |
COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score.